| Myelodysplastic Syndrome with Excess Blasts studied in …STUDIED_INderived10 of 76show all (up to 200) |
|---|
| → studied in | NCT06484062Phase 1 · recruiting Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes · condition mapped CURATED_BROADER · 76 trials mapped (24 active) | — | — | Myelodysplastic Syndrome/Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03779854Phase 2 · active not recruiting Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant · condition mapped ALIAS · 76 trials mapped (24 active) | — | — | Myelodysplastic Syndrome with Excess Blasts | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03839771Phase 3 · active not recruiting A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy · condition mapped ALIAS · 76 trials mapped (24 active) | — | — | Myelodysplastic Syndrome/Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00801489Phase 2 · recruiting Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome · condition mapped ONTOLOGY_EXACT · 76 trials mapped (24 active) | — | — | Myelodysplastic Syndrome with Excess Blasts | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02530034Phase 1 · active not recruiting Hu8F4 in Treating Patients With Advanced Hematologic Malignancies · condition mapped ALIAS · 76 trials mapped (24 active) | — | — | Myelodysplastic Syndrome with Excess Blasts | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03816319Phase 1 · active not recruiting TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes With Increased Blasts · condition mapped ONTOLOGY_EXACT · 76 trials mapped (24 active) | — | — | Myelodysplastic Syndrome with Excess Blasts | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01522976Phase 2 · active not recruiting Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia · condition mapped ONTOLOGY_EXACT · 76 trials mapped (24 active) | — | — | Myelodysplastic Syndrome with Excess Blasts | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03383575Phase 2 · recruiting Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome · condition mapped ONTOLOGY_EXACT · 76 trials mapped (24 active) | — | — | Myelodysplastic Syndrome with Excess Blasts | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05600894Phase 2 · active not recruiting Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm · condition mapped ONTOLOGY_EXACT · 76 trials mapped (24 active) | — | — | Myelodysplastic Syndrome with Excess Blasts | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00392353Phase 1/Phase 2 · active not recruiting Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia · condition mapped ONTOLOGY_EXACT · 76 trials mapped (24 active) | — | — | Myelodysplastic Syndrome with Excess Blasts | 1 | Observed | clinicaltrials | graph → |